Cogent Biosciences (NASDAQ:COGT - Get Free Report) released its earnings results on Tuesday. The technology company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.07), Briefing.com reports. During the same quarter in the previous year, the firm posted ($0.64) EPS.
Cogent Biosciences Stock Performance
NASDAQ COGT traded up $0.02 during trading hours on Wednesday, hitting $10.40. The company had a trading volume of 2,608,803 shares, compared to its average volume of 1,428,273. The firm has a 50 day simple moving average of $11.08 and a 200 day simple moving average of $9.53. Cogent Biosciences has a 52 week low of $3.67 and a 52 week high of $12.61. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of -4.19 and a beta of 1.72.
Analysts Set New Price Targets
A number of equities research analysts recently commented on COGT shares. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price target on shares of Cogent Biosciences in a report on Monday, November 4th. Wedbush restated a "neutral" rating and issued a $11.00 target price on shares of Cogent Biosciences in a research note on Tuesday. Citigroup increased their price target on Cogent Biosciences from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Tuesday, September 24th. Robert W. Baird boosted their price objective on Cogent Biosciences from $8.00 to $10.00 and gave the company a "neutral" rating in a research note on Thursday, September 5th. Finally, Needham & Company LLC dropped their price objective on shares of Cogent Biosciences from $16.00 to $15.00 and set a "buy" rating on the stock in a report on Wednesday. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $14.50.
Read Our Latest Stock Report on Cogent Biosciences
Cogent Biosciences Company Profile
(
Get Free Report)
Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Featured Articles
Before you consider Cogent Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cogent Biosciences wasn't on the list.
While Cogent Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
